文献速递中枢神经肿瘤放疗胸部肿瘤放疗

奥希替尼联合颅脑放疗对比奥希替尼单药治疗伴EGFR激活突变和脑转移的NSCLC患者的疗效:一项回顾性研究

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
PubMed 文献 · Radiat Oncol · 2021-12-05

该回顾性研究纳入61例伴脑转移的EGFR突变晚期NSCLC患者,比较奥希替尼联合颅脑放疗与奥希替尼单药的疗效。两组颅内和全身ORR、DCR及iPFS无显著差异,总生存也无显著差异(HR=0.895,P=0.826)。在L858R突变亚组中联合放疗组OS更长(P=0.046),而在外显子19缺失亚组中单药组OS更长(P=0.011)。

要点

  • 奥希替尼联合颅脑放疗与单药相比,颅内和全身ORR、DCR及iPFS无显著差异。
  • 联合放疗组中位OS为29.20个月,单药组为26.13个月(HR=0.895,P=0.826)。
  • L858R突变亚组联合放疗OS更长(P=0.046),外显子19缺失亚组单药OS更长(P=0.011)。

核心结论

  • 在EGFR阳性伴脑转移的NSCLC患者中,奥希替尼联合放疗的疗效与奥希替尼单药相似。
  • 对于L858R突变患者,奥希替尼联合放疗可能比奥希替尼单药带来更多获益。

研究设计与样本

  • 回顾性研究,纳入2015年12月至2020年8月期间接受奥希替尼治疗的晚期NSCLC伴脑转移患者61例。
  • 40例接受奥希替尼单药治疗,21例接受奥希替尼联合放疗。
  • 放疗方式包括全脑放疗(WBRT,n=14)、全脑放疗同步整合推量(WBRT-SIB,n=5)和立体定向放射外科(SRS,n=2)。
  • 两组既往系统治疗中位数为1。

主要发现

  • 两组颅内和全身ORR及DCR无显著差异。
  • 两组iPFS无差异(中位iPFS:16.67 vs. 13.50个月,P=0.836)。
  • 联合放疗组中位OS为29.20个月,单药组为26.13个月(HR=0.895,P=0.826)。
  • 在31例L858R突变亚组中,联合放疗组OS更长(P=0.046)。
  • 在30例外显子19缺失亚组中,单药组OS长于联合放疗组(P=0.011)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The study aimed to compare the efficacy of osimertinib plus cranial radiotherapy (RT) with osimertinib alone in advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations and brain metastases (BMs). METHODS: The clinical data of advanced NSCLC patients with BMs who received osimertinib were retrospectively collected. The patients were assigned to one of the two groups according to the therapeutic modality used: the osimertinib monotherapy group or the osimertinib plus RT group. RESULTS: This was a retrospective study and 61 patients were included from December 2015 to August 2020. Forty patients received osimertinib monotherapy, and twenty-one patients received osimertinib plus RT. Radiotherapy included whole-brain radiation therapy (WBRT, n = 14), WBRT with simultaneous integrated boost (WBRT-SIB, n = 5) and stereotactic radiosurgery (SRS, n = 2). The median number of prior systemic therapies in the two groups was one. Intracranial and systemic ORR and DCR were not significantly different between the two groups. No difference in iPFS was observed between the two groups (median iPFS: 16.67 vs. 13.50 months, P = 0.836). The median OS was 29.20 months in the osimertinib plus RT group compared with 26.13 months in the osimertinib group (HR = 0.895, P = 0.826). In the L858R mutational subgroup of 31 patients, the osimertinib plus RT group had a longer OS (P = 0.046). In the exon 19 deletion mutational subgroup of 30 patients, OS in the osimertinib alone group was longer than that in the osimertinib plus RT group (P = 0.011). The incidence of any-grade adverse events was not significantly different between the osimertinib plus RT group and the osimertinib alone group (47.6% vs. 32.5%, P = 0.762). However, six patients (28.5%) experienced leukoencephalopathy in the osimertinib plus RT group, and 50% (3/6) of the leukoencephalopathy was greater than or equal to grade 3. CONCLUSION: The therapeutic effect of osimertinib with RT was similar to that of osimertinib alone in EGFR-positive NSCLC patients with BM. However, for patients with the L858R mutation, osimertinib plus RT could provide more benefit than osimertinib alone.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhai X, Li W, Li J, et al. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study. Radiat Oncol. 2021. PMID: 34865626. doi:10.1186/s13014-021-01955-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。